Australia's most generous blood plasma donor dies aged 88
James Harrison, a retired state railway department clerk, died in a nursing home where he had lived for five weeks on the Central Coast of New South Wales state on Feb. 17, according to his grandson, Jarrod Mellowship.
Harrison had been surprised to be recognized by Guinness World Records in 2005 as the person who had donated the most blood plasma in the world, Mellowship said.
Despite an aversion to needles, he made 1,173 donations after he turned 18 in 1954 until he was forced to retire in 2018, aged 81.
'He did it for the right reasons. As humble as he was, he did like the attention. But he would never do it for the attention,' Mellowship said.
The record was beaten in 2022 by American Brett Cooper from Walker, Michigan.
Australian Red Cross Blood Service pays tribute to donor
The Australian Red Cross Blood Service said Harrison was renowned as the 'Man with the Golden Arm.'
He was credited with saving the lives of 2.4 million babies through his plasma donations, the national agency responsible for collecting and distributing blood products, also known as Lifeblood, said in a statement.
Harrison's plasma contained a rare antibody known as anti-D. The antibody is used to make injections that protect unborn babies from a deadly condition called Haemolytic Disease of the Fetus and Newborn, or HDFN. The disease causes a pregnant woman's immune system to attack the fetus's red blood cells.
Australia has only 200 anti-D donors who help 45,000 mothers and their babies annually.
Lifeblood chief executive Stephen Cornelissen said Harrison had hoped that someone in Australia would one day beat his donation record.
'James was a remarkable, stoically kind and generous person who was committed to a lifetime of giving and he captured the hearts of many people around the world,' Cornelissen said in a statement.
'It was James' belief that his donations were no more important than any other donors' and that everyone can be special in the same way that he was,' Cornelissen added.
Antibody helps donor's family
Mellowship said his mother, Tracey Mellowship, Harrison's daughter, needed the treatment when he and his brother Scott were born.
Jarrod Mellowship said his own wife, Rebecca Mellowship, also needed the treatment when three of their four children were born.
There is speculation that Harrison developed a high concentrations of anti-D as a result of his own blood transfusions during major lung surgery when he was 14 years old.
'After the surgery, his dad Reg told grandad you're only really alive because people donated blood,' Jarrod Mellowship said. 'The day he turned 18, he started donating.'
The application of anti-D in fighting HDFN was not discovered until the 1960s.
Harrison was born in Junee in New South Wales. He is survived by his sister Margaret Thrift, his daughter, two grandsons and four great grandchildren.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 days ago
- The Independent
New blood pressure guidelines recommend cutting back on alcohol
New guidelines from the American Heart Association and American College of Cardiology address high blood pressure, a condition affecting nearly half of US adults and increasing risks of heart attack, stroke, and dementia. A primary recommendation is to significantly reduce sodium intake, with an ideal daily limit of 1,500 milligrams, down from the current average consumption of 3,400 milligrams. The guidelines also advise limiting alcohol consumption to no more than two drinks daily for men and one for women, with an emphasis on avoiding alcohol entirely due to its links to various diseases. Most dietary sodium comes from packaged and prepared foods, highlighting the need to check labels and make low-sodium choices. Further lifestyle recommendations include maintaining a nutritious diet, a healthy weight, regular physical activity, and managing stress to prevent or treat high blood pressure.
Spectator
3 days ago
- Spectator
Mounjaro won't be the last drug company to bow to Trump
If you need to lose a few pounds after enjoying the French or Italian food a little too much on your summer holiday, there might soon be a problem. The cost of one of the new weight loss drugs that has become so popular in recent months is about to get a lot more expensive. The American drugs giant Eli Lilly doubling the price of Mounjaro in the UK. The price of one diet pill does not make a great deal of difference. The trouble is, the decision was prompted by President Trump's determination to make the cost of medicines a lot fairer between the United States and the rest of the world. This is going to end up costing Britain, along with many other countries, a lot of money. Eli Lilly will be increasing the British price of Mounjaro, the most popular and effective weight loss injection, from £92 for a medium-sized dose to £180, and from £122 to £330 for a stronger version. The reason is simple. President Trump, with his typically blunt language, complained about how a friend of his brought 'the fat drug' in London at a far lower price than in the US despite being 'the same box made in the same plant by the same company'. More broadly, President Trump has made a big issue of the huge differences in drug prices between the US and other countries. He has imposed tariffs that could go as high as 250 per cent to force the major pharmaceutical companies to bring their manufacturing onshore and lower prices for American patients. Eli Lilly's response, quite rationally, has been to increase the price in the UK to start to close the gap and keep the President happy. Eli Lilly won't be the last pharmaceutical company to do this. Truth be told, President Trump has a point about the unfairness of drug prices in his country. On average, medicines cost 2.7 times more in the US than they do in the rest of the world. That might make sense for poor countries, but it is hard to see why developed economies in Europe, the Gulf or Asia should pay so much less for medicines than America does. In effect, the US subsidises the rest of the world, paying for the huge cost of research while the rest of the world gets drugs at far less than they would otherwise cost. But if that is rebalanced, medicines will inevitably get a lot more expensive, both for private patients and in time for the NHS as well. Given that the UK spends £34 billion a year on pharmaceuticals and that £19 billion of that comes from the NHS, that is going to be a very big bill – and one that we can barely afford.
Daily Mirror
3 days ago
- Daily Mirror
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.
